Distinct distribution and prognostic significance of molecular subtypes of breast cancer in Chinese women: A population-based cohort study

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Su, Yinghao ^a   Zheng, Ying ^b   Zheng, Wei ^a   Gu, Kai ^b   Chen, Zhi ^a   Li, Guoliang ^a   Cai, Qiuyin ^a   Lu, Wei ^b   Shu, Xiao O ^a  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

^b Shanghai Institute of Preventive Medicine   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; INTERFERON; INTERLEUKIN 2; PROGESTERONE RECEPTOR; ESTROGEN RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CLASSIFICATION; CANCER GRADING; CANCER IMMUNOTHERAPY; CANCER SURVIVOR; CHINESE; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE FREE INTERVAL; ETHNIC DIFFERENCE; FAMILY HISTORY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHOKINE ACTIVATED KILLER CELL; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PROGNOSIS; PROTEIN DETERMINATION; TOTAL QUALITY MANAGEMENT; TUMOR VOLUME; AGE DISTRIBUTION; ASIAN; BREAST TUMOR; CHINA; CLASSIFICATION; DISEASE FREE SURVIVAL; ETHNOLOGY; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; STATISTICS; TISSUE MICROARRAY;

ADULT; AGE DISTRIBUTION; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BREAST NEOPLASMS; CHINA; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TISSUE ARRAY ANALYSIS;

EID: 79960198194     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-292     Document Type: Article

References (36)

1. Di CS, Baselga J. Management of breast cancer with targeted agents: importance of heterogenicity. Nat Rev Clin Oncol 2010, 7:139-147. 10.1038/nrclinonc.2009.234, 20125090.
2. van 't Veer LJ, Dai H, Van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415:530-536. 10.1038/415530a, 11823860.
3. Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, Martiat P, Fox SB, Harris AL, Liu ET. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 2003, 100:10393-10398. 10.1073/pnas.1732912100, 193572, 12917485.
4. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006, 295:2492-2502. 10.1001/jama.295.21.2492, 16757721.
5. Nguyen PL, Taghian AG, Katz MS, Niemierko A, Abi Raad RF, Boon WL, Bellon JR, Wong JS, Smith BL, Harris JR. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol 2008, 26:2373-2378. 10.1200/JCO.2007.14.4287, 18413639.
6. Morris GJ, Naidu S, Topham AK, Guiles F, Xu Y, McCue P, Schwartz GF, Park PK, Rosenberg AL, Brill K, Mitchell EP. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database. Cancer 2007, 110:876-884. 10.1002/cncr.22836, 17620276.
7. Millikan RC, Newman B, Tse CK, Moorman PG, Conway K, Dressler LG, Smith LV, Labbok MH, Geradts J, Bensen JT, Jackson S, Nyante S, et al. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 2008, 109:123-139. 10.1007/s10549-007-9632-6, 2443103, 17578664.
8. Parise CA, Bauer KR, Brown MM, Caggiano V. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004. Breast J 2009, 15:593-602. 10.1111/j.1524-4741.2009.00822.x, 19764994.
9. Telli ML, Kurian AW, Chang ET, Keegan TH, Ford JM, Gomez SL. Asian race and breast cancer subtypes: A study from the California Cancer Registry. Breast Cancer Res Treat 2011, 127:471-478. 10.1007/s10549-010-1173-8, 20957431.
10. Liu ZB, Liu GY, Yang WT, Di GH, Lu JS, Shen KW, Shen ZZ, Shao ZM, Wu J. Triple-negative breast cancer types exhibit a distinct poor clinical characteristic in lymph node-negative Chinese patients. Oncol Rep 2008, 20:987-994.
11. Yin WJ, Lu JS, Di GH, Lin YP, Zhou LH, Liu GY, Wu J, Shen KW, Han QX, Shen ZZ, Shao ZM. Clinicopathological features of the triple-negative tumors in Chinese breast cancer patients. Breast Cancer Res Treat 2009, 115:325-333. 10.1007/s10549-008-0096-0, 18563552.
12. Lin Y, Yin W, Yan T, Zhou L, Di G, Wu J, Shen Z, Shao Z, Lu J. Site-specific relapse pattern of the triple negative tumors in Chinese breast cancer patients. BMC Cancer 2009, 9:342. 10.1186/1471-2407-9-342, 2760577, 19778431.
13. Zhao J, Liu H, Wang M, Gu L, Guo X, Gu F, Fu L. Characteristics and prognosis for molecular breast cancer subtypes in Chinese women. J Surg Oncol 2009, 100:89-94. 10.1002/jso.21307, 19544363.
14. Xing P, Li J, Jin F. A case-control study of reproductive factors associated with subtypes of breast cancer in Northeast China. Med Oncol 2010, 27:926-931. 10.1007/s12032-009-9308-7, 19771534.
15. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007, 131:18-43.
16. Shu XO, Zheng Y, Cai H, Gu K, Chen Z, Zheng W, Lu W. Soy food intake and breast cancer survival. JAMA 2009, 302:2437-2443. 10.1001/jama.2009.1783, 2874068, 19996398.
17. Su Y, Shrubsole MJ, Ness RM, Cai Q, Kataoka N, Washington K, Zheng W. Immunohistochemical expressions of Ki-67, cyclin D1, beta-catenin, cyclooxygenase-2, and epidermal growth factor receptor in human colorectal adenoma: a validation study of tissue microarrays. Cancer Epidemiol Biomarkers Prev 2006, 15:1719-1726. 10.1158/1055-9965.EPI-05-0946, 16985035.
18. Tavassoli FA, Devilee P. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs 2003, London, IARC Press.
19. Rakha EA, El-Sayed ME, Lee AH, Elston CW, Grainge MJ, Hodi Z, Blamey RW, Ellis IO. Prognostic significance of Nottingham histologic grade in invasive breast carcinoma. J Clin Oncol 2008, 26:3153-3158. 10.1200/JCO.2007.15.5986, 18490649.
20. Diaz LK, Sahin A, Sneige N. Interobserver agreement for estrogen receptor immunohistochemical analysis in breast cancer: a comparison of manual and computer-assisted scoring methods. Ann Diagn Pathol 2004, 8:23-27. 10.1016/j.anndiagpath.2003.11.004, 15129906.
21. Fisher ER, Anderson S, Dean S, Dabbs D, Fisher B, Siderits R, Pritchard J, Pereira T, Geyer C, Wolmark N. Solving the dilemma of the immunohistochemical and other methods used for scoring estrogen receptor and progesterone receptor in patients with invasive breast carcinoma. Cancer 2005, 103:164-173. 10.1002/cncr.20761, 15565575.
22. Zarcone M, Amodio R, Campisi I, Cusimano R, Dolcemascolo C, Miceli V, Traina A, Macaluso M. Application of a new classification to a breast tumor series from a population-based cancer registry: demographic, clinical, and prognostic features of incident cases, Palermo Province, 2002-2004. Ann N Y Acad Sci 2009, 1155:222-226. 10.1111/j.1749-6632.2008.03693.x, 19250207.
23. Yang XR, Sherman ME, Rimm DL, Lissowska J, Brinton LA, Peplonska B, Hewitt SM, Anderson WF, Szeszenia-Dabrowska N, Bardin-Mikolajczak A, Zatonski W, Cartun R, et al. Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev 2007, 16:439-443. 10.1158/1055-9965.EPI-06-0806, 17372238.
24. Lebeau A, Deimling D, Kaltz C, Sendelhofert A, Iff A, Luthardt B, Untch M, Lohrs U. Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. J Clin Oncol 2001, 19:354-363.
25. Perez EA, Roche PC, Jenkins RB, Reynolds CA, Halling KC, Ingle JN, Wold LE. HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. Mayo Clin Proc 2002, 77:148-154. 10.4065/77.2.148, 11838648.
26. John EM, Miron A, Gong G, Phipps AI, Felberg A, Li FP, West DW, Whittemore AS. Prevalence of Pathogenic BRCA1 Mutation Carriers in 5 US Racial/Ethnic Groups. JAMA 2007, 298:2869-2876. 10.1001/jama.298.24.2869, 18159056.
27. Suter NM, Ray RM, Hu YW, Lin MG, Porter P, Gao DL, Zaucha RE, Iwasaki LM, Sabacan LP, Langlois MC, Thomas DB, Ostrander EA. BRCA1 and BRCA2 mutations in women from Shanghai China. Cancer Epidemiol Biomarkers Prev 2004, 13:181-189. 10.1158/1055-9965.EPI-03-0196, 14973102.
28. Lin CH, Liau JY, Lu YS, Huang CS, Lee WC, Kuo KT, Shen YC, Kuo SH, Lan C, Liu JM, Kuo WH, Chang KJ, Cheng AL. Molecular subtypes of breast cancer emerging in young women in Taiwan: evidence for more than just westernization as a reason for the disease in Asia. Cancer Epidemiol Biomarkers Prev 2009, 18:1807-1814. 10.1158/1055-9965.EPI-09-0096, 19505913.
29. Kwan ML, Kushi LH, Weltzien E, Maring B, Kutner SE, Fulton RS, Lee MM, Ambrosone CB, Caan BJ. Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors. Breast Cancer Res 2009, 11:R31. 10.1186/bcr2261, 2716499, 19463150.
30. Ismail-Khan R, Bui MM. A review of triple-negative breast cancer. Cancer Control 2010, 17:173-176.
31. Loi S, Sotiriou C, Buyse M, Rutgers E, Van't Veer L, Piccart M, Cardoso F. Molecular forecasting of breast cancer: time to move forward with clinical testing. J Clin Oncol 2006, 24:721-722. 10.1200/JCO.2005.04.6524, 16446348.
32. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003, 100:8418-8423. 10.1073/pnas.0932692100, 166244, 12829800.
33. Bhargava R, Dabbs DJ. Luminal B breast tumors are not HER2 positive. Breast Cancer Res 2008, 10:404. 10.1186/bcr2134, 2614503, 18831725.
34. Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009, 101:736-750. 10.1093/jnci/djp082, 2684553, 19436038.
35. Florescu A, Amir E, Bouganim N, Clemons M. Immune therapy for breast cancer in 2010-hype or hope?. Curr Oncol 2011, 18:e9-e18. 3031364, 21331271.
36. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer. J Clin Oncol 2010, 28:2784-2795. 10.1200/JCO.2009.25.6529, 2881855, 20404251.